C4 Therapeutics Inc
(NAS:CCCC)
$
4.155
+0.040 (+0.97%)
Market Cap: 511.17 Mil
Enterprise Value: 314.36 Mil
PE Ratio: 0
PB Ratio: 2.07
GF Score: 49/100 C4 Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022 / 10:00PM GMT
Release Date Price:
$9.08
(+2.48%)
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
And why don't we get going with the Q&A? Well, first of all, welcome.
Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director
Great. Thanks for having us.
Questions & Answers
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
And a pleasure to be hosting you. So why don't we talk about C4's development strategy a little bit? You guys tend to go into indications that have proven targets, but these indications are very crowded. So when I look at it, is basically derisked from a science or biology perspective, but very high bar for success commercially. Is that a fair statement?
Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director
Well, I think what you're seeing is the strategy play out the company started with, which is a very classic strategy for a new platform company where you don't want to add
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot